[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Irelli, A., Sirufo, M.M., D’Ugo, C., Ginaldi, L. and De Martinis, M. (2020) Real-Life Use of Denosumab 120 mg Every 12 Weeks in Prolonged Treatment over 2 Years of Patients with Breast Cancer Bone Metastases. Journal of B.U.ON., 25, 1799-1804.
|
[3]
|
Tahara, R.K., Brewer, T.M., Theriault, R.L. and Ueno, N.T. (2019) Bone Metastasis of Breast Cancer. In: Ahmad, A., Eds., Breast Cancer Metastasis and Drug Resistance, Vol. 1152, Springer, Cham, 105-129.
https://doi.org/10.1007/978-3-030-20301-6_7
|
[4]
|
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M. and Fabbri, A. (2019) RANKL/RANK/OPG System beyond Bone Remodeling: Involvement in Breast Cancer and Clinical Perspectives. Journal of Experimental & Clinical Cancer Research, 38, Article No. 12. https://doi.org/10.1186/s13046-018-1001-2
|
[5]
|
Kitazawa, S. and Kitazawa, R. (2002) RANK Ligand Is a Prereq-uisite for Cancer-Associated Osteolytic Lesions. The Journal of Pathology, 198, 228-236. https://doi.org/10.1002/path.1199
|
[6]
|
Yin, J.J., Pollock, C.B. and Kelly, K. (2005) Mechanisms of Cancer Metas-tasis to the Bone. Cell Research, 15, 57-62.
https://doi.org/10.1038/sj.cr.7290266
|
[7]
|
Min, J.K., Kim, Y.M., Kim, Y.M., Kim, E.C., Gho, Y.S., Kang, I.J., Lee, S.Y., Kong, Y.Y. and Kwon, Y.G. (2003) Vascular Endothelial Growth Factor Up-Regulates Expression of Recep-tor Activator of NF-κB (RANK) in Endothelial Cells. Concomitant Increase of Angiogenic Responses to RANK Ligand. Journal of Biological Chemistry, 278, 39548- 39557. https://doi.org/10.1074/jbc.M300539200
|
[8]
|
Body, J.J., Bone, H.G., De Boer, R.H., Stopeck, A., Van Poznak, C., Damiao, R., et al. (2015) Hypocalcaemia in Patients with Metastatic Bone Disease Treated with Denosumab. European Journal of Cancer, 51, 1812-1821.
https://doi.org/10.1016/j.ejca.2015.05.016
|
[9]
|
Lewiecki, E.M. (2009) Denosumab Update. Current Opinion in Rheumatology, 21, 369-373.
https://doi.org/10.1097/BOR.0b013e32832ca41c
|
[10]
|
Yee, A.J. and Raje, N.S. (2012) Denosumab, a RANK Lig-and Inhibitor, for the Management of Bone Loss in Cancer Patients. Clinical Interventions in Aging, 7, 331-338. https://doi.org/10.2147/CIA.S14566
|
[11]
|
Gül, G., Sendur, M.A., Aksoy, S., Sever, A.R. and Altundag, K. (2016) A Comprehensive Review of Denosumab for Bone Metastasis in Patients with Solid Tumors. Current Medical Research and Opinion, 32, 133-145.
https://doi.org/10.1185/03007995.2015.1105795
|
[12]
|
Gnant, M., Pfeiler, G., Steger, G.G., Egle, D., Greil, R., Fitzal, F., Wette, V., Balic, M., Haslbauer, F., Melbinger- Zeinitzer, E., Bjelic-Radisic, V., Jakesz, R., Marth, C., Sevelda, P., Mlineritsch, B., Exner, R., Fesl, C., Frantal, S., Singer, C.F. and Austrian Breast and Colorectal Cancer Study Group (2019) Adjuvant Denosumab in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer (ABCSG-18): Disease-Free Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncol-ogy, 20, 339-351.
https://doi.org/10.1016/S1470-2045(18)30862-3
|
[13]
|
Zhang, C., Zhang, F., Liang, G., Zeng, X., Yu, W., Jiang, Z., et al. (2018) Denosumab versus Zoledronic Acid for Preventing Symptomatic Skeletal Events in Asian Postmenopausal Women with Oestrogen-Receptor-Positive Advanced Breast Cancer: An Outcome Analyses with a Mean Follow-Up of 3 Years. BMC Musculoskeletal Disorders, 19, Article No. 424. https://doi.org/10.1186/s12891-018-2338-6
|
[14]
|
Fizazi, K., Lipton, A., Mariette, X., Body, J.J., Rahim, Y., Gralow, J.R., Gao, G., Wu, L., Sohn, W. and Jun, S. (2009) Randomized Phase II Trial of Denosumab in Patients with Bone Metastases from Prostate Cancer, Breast Cancer, or Other Neoplasms after Intravenous Bisphosphonates. Journal of Clinical Oncology, 27, 1564-1571.
https://doi.org/10.1200/JCO.2008.19.2146
|
[15]
|
O’Carrigan, B., Wong, M.H.F., Willson, M.L., Stockler, M.R., Pavlakis, N. and Goodwin, A. (2017) Bisphosphonates and Other Bone Agents for Breast Cancer. Cochrane Database of Systematic Reviews, No. 10, Article No. CD003474.
https://doi.org/10.1002/14651858.CD003474.pub4
|
[16]
|
Baron, R., Ferrari, S. and Russell, R.G. (2011) Deno-sumab and Bisphosphonates: Different Mechanisms of Action and Effects. Bone, 48, 677-692. https://doi.org/10.1016/j.bone.2010.11.020
|
[17]
|
Lipton, A., Steger, G.G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K.S., Coleman, R., Paterson, A.H., Peterson, M.C., Fan, M., Kinsey, A. and Jun, S. (2007) Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Pa-tients with Breast Cancer-Related Bone Metastases. Journal of Clinical Oncology, 25, 4431-4437. https://doi.org/10.1200/JCO.2007.11.8604
|
[18]
|
Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S. and Braun, A. (2010) Denosumab Compared with zoledronic Acid for the Treatment of Bone Metastases in Patients with Advanced Breast Cancer: A Randomized, Double- Blind Study. Journal of Clinical Oncology, 28, 5132-5139. https://doi.org/10.1200/JCO.2010.29.7101
|